Efficacy of bevacizumab nasal spray for the treatment of epistaxis in Rendu- Osler disease [Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler]

Trial Profile

Efficacy of bevacizumab nasal spray for the treatment of epistaxis in Rendu- Osler disease [Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler]

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Epistaxis
  • Focus Therapeutic Use
  • Acronyms ALEGORI
  • Most Recent Events

    • 12 Dec 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
    • 06 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top